Sanofi (SNYNF) Cash & Equivalents (2009 - 2026)

Sanofi has reported Cash & Equivalents for 18 years, with the latest figure at $7.4 billion in Q2 2026.

• Quarterly Cash & Equivalents fell 57.55% year-over-year to $7.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.4 billion (down 57.55% YoY) and the FY2025 annual result came in at $8.9 billion, up 12.09% from the prior year.
• Cash & Equivalents improved to $7.4 billion in Q2 2026 per SNYNF's latest filing, from $6.9 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $17.4 billion in Q2 2025 and troughed at $6.9 billion in Q1 2026.
• A 5-year average of $9.4 billion and a median of $8.7 billion in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 137.59% in 2025, then sank 57.55% in 2026.
• Over 5 years, Cash & Equivalents stood at $13.0 billion in 2022, then slipped by 27.88% to $9.4 billion in 2023, then declined by 15.15% to $8.0 billion in 2024, then rose by 12.09% to $8.9 billion in 2025, then declined by 17.19% to $7.4 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.4 billion, $6.9 billion, and $8.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.